Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Neuroblastoma is the second most frequent cause for death from cancer in childhood. Already
one year after diagnosis of recurrence from high risk neuroblastoma, 75% of the patients
experience further progression.
Metronomic therapy is targeting not only the tumor cell, but also the tumor supplying
vasculature and the interactions between Tumor and immune cells. The toxicity is expected to
be low due to the low (but continuous) dosing of drugs.
The study investigates the tolerance and the efficacy of a new combination of five drugs
consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating immune
response, ant-neuroblastic), cyclophosphamide (antiangiogenetic, anti-neuroblastic),
etoposide (antiangiogenetic, anti-neuroblastic), and vinblastin (antiangiogenetic,
anti-neuroblastic). Vinblastin is scheduled every 14 days intravenously, all other drugs are
applied daily throughout 365 days (except etoposide for 4x3 weeks). The efficacies of each of
the drugs have been demonstrated in vitro and in vivo in animal studies. All drugs have been
used in children for other conditions. From those experiences low toxicities and a favorable
Quality of life are expected.